Phase 1 cancer trials
What is a Phase 1 cancer trial?
A Phase 1 trial is usually the first study of a new cancer treatment in people. It is built around safety, side effects, and finding the right dose, not around proving the treatment works better than what is already used. Phase 1 trials are small, often about 15 to 30 people, and participants are watched closely for unexpected side effects.
This is not clinical evidence and not medical advice. It does not replace your care team. Discuss anything here with your clinician before you act on it. Product questions are on the FAQ.
Made by Triangle.
Safety, dose, how many people, how closely they are watched. Not a test of whether the treatment works.
Does joining a Phase 1 trial mean standard care has failed?
Not automatically. Eligibility is written into the protocol. Some trials enrol people after standard options; others enrol earlier, in narrower settings. Read that on the ClinicalTrials.gov listing, with your care team.
How many people are in a Phase 1 cancer trial?
Small groups, typically around 15 to 30. Later phases grow: roughly 50 to 100 in Phase 2, and from a hundred to several thousand in Phase 3.
How closely are people watched in a Phase 1 trial?
Closely. Participants are monitored for unexpected side effects. If a safety concern comes up, the study is paused and examined. An institutional review board reviews the protocol before enrolment and at least yearly after that.
Can I join a Phase 1 trial if I've had brain metastases, am older, or have HIV or hepatitis?
It depends on that trial's protocol. A November 2026 FDA draft guidance does not change those criteria on its own. The draft covers early-phase trials in solid tumors, not blood cancers, and it is not binding on FDA or the public. In the draft, FDA says unnecessarily restrictive eligibility criteria may slow enrolment, limit access to early-phase trials, and make the results less applicable to the people who will ultimately use the drug. It says that, in general, protocols should not impose upper age limitations, and that if one is proposed, adequate justification should be provided. It says thoughtful consideration should be given to the potential inclusion of people with brain metastases, while maintaining adequate patient safety, and of people with HIV, hepatitis B, or hepatitis C. Unless scientifically justified or necessary for the study's goals, FDA generally does not recommend time-based wash-out periods. Eligibility after a prior treatment should be based on recovery from clinically significant side effects. You can ask the study team whether a given exclusion is required for this drug.
See recruiting clinical trials →
Sources
- FDA: The Drug Development Process — Step 3: Clinical ResearchPhase 1 is primarily about safety, side effects, and dosing in people.
- NCI: How Do Clinical Trials Work?Phase 1 trials enrol around 15 to 30 people; Phase 2 50 to 100; Phase 3 from 100 to several thousand.
- NCI: Facts About Clinical TrialsPhase 1 participants are closely monitored for side effects and adverse events; a trial is stopped and examined if a safety concern arises.
- NCI: Are Clinical Trials Safe?IRBs review protocols before a trial accepts patients and yearly after that.
- Early-Phase IND Protocol Recommendations for Solid Tumors, Draft Guidance for Industry (FDA, November 2026)This November 2026 document is draft guidance for industry. When finalized, it will represent FDA's current thinking on the topic. It does not establish any rights for any person and is not binding on FDA or the public. The guidance is specific to solid tumors and does not address protocols for investigational drugs intended to treat hematologic malignancies.
- Early-Phase IND Protocol Recommendations for Solid Tumors, Draft Guidance for Industry (FDA, November 2026)Unnecessarily restrictive eligibility criteria may slow patient accrual, limit patient access to early-phase trials, and lead to trial results that have limited applicability in the patient population that will ultimately use the drug.
- Early-Phase IND Protocol Recommendations for Solid Tumors, Draft Guidance for Industry (FDA, November 2026)In general, protocols should not impose upper age limitations. If an upper age limitation is proposed, adequate justification should be provided.
- Early-Phase IND Protocol Recommendations for Solid Tumors, Draft Guidance for Industry (FDA, November 2026)Thoughtful consideration should be given to the potential inclusion of patients with brain metastases in early-phase trials. Patients with brain metastases should be included in clinical trials in a way that contributes to a greater understanding of the efficacy and safety profile of the investigational drug while maintaining adequate patient safety.
- Early-Phase IND Protocol Recommendations for Solid Tumors, Draft Guidance for Industry (FDA, November 2026)Thoughtful consideration should be given to the potential inclusion of patients infected with human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) in cancer clinical trials. Eligibility criteria should be designed in a manner that is appropriate for a given cancer, investigational drug, and intended use population.
- Early-Phase IND Protocol Recommendations for Solid Tumors, Draft Guidance for Industry (FDA, November 2026)Unless scientifically justified or necessary to achieve the goals of the clinical investigation, FDA generally does not recommend time-based wash-out and recovery periods. Eligibility after prior therapy or intervention should be based on recovery from clinically significant adverse events from the therapy or intervention preceding study enrollment.
Triangle